Citizens raised the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $28 and keeps an Outperform rating on the shares. Intellia’s Phase 3 HAELO outcome are positive for hereditary angioedema patients, with the potential to deliver a true one-and-done therapy that offers a clearly differentiated option, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA)
- Cathie Wood’s ARK Investment buys 264K shares of Intellia Therapeutics today
- Intellia Therapeutics announces $150M common stock offering
- Intellia Therapeutics price target raised to $30 from $27 at Chardan
- Intellia Therapeutics price target raised to $35 from $29 at Leerink